Two biotechnology firms partner to develop new AI-powered biopharmaceuticals
The collaboration will result in development of next-generation antibody-drug conjugates.
- byAPR Team
- 05 Nov, 2024
- 1 Mins
.jpg)
Lonza-owned biotechnology firm Synaffix has licensed its antibody-drug conjugate (ADC) technology to BigHat Biosciences, enabling BigHat to use its advanced machine-learning antibody design platform to develop a novel ADC pipeline.
This collaboration grants BigHat targeted access to Synaffix’s late-stage, site-specific ADC technology platform, which transforms antibodies into exclusive, best-in-class ADCs.
Additionally, BigHat will benefit from Lonza’s comprehensive ADC capabilities, creating a robust foundation for end-to-end ADC development.
“We are excited to be at the forefront of next-generation ADC R&D by joining forces with BigHat and its AI/ML-enabled antibody discovery and development platform,” said Peter van de Sande, Head of Synaffix. “BigHat is the ideal partner, and we look forward to supporting them at every stage of the ADC development and manufacturing process within the Lonza network.”
READ ALSO: AbbVie and EvolveImmune Therapeutics partner to innovate new cancer biotherapies
BigHat’s AI/ML-driven antibody design platform, Milliner™, integrates state-of-the-art machine learning with a high-throughput synthetic biology wet lab to engineer antibodies with advanced functionalities and enhanced biophysical properties.
This approach streamlines the design and validation of antibodies and therapeutic proteins for critical diseases, expediting discovery and validation.
BigHat’s next-generation ADC, optimized on the Milliner platform for precise tumor targeting and drug-like properties, is currently at the IND-enabling stage, marking BigHat’s first anticipated clinical program.
The product’s safety and efficacy are expected to benefit from Synaffix’s conjugation and payload technologies through the Lonza partnership.
“BigHat is leveraging our AI-driven Milliner™ platform to develop advanced biologics that offer safer, more effective treatments for hard-to-treat cancers,” said Mark DePristo, CEO of BigHat Biosciences. “We are thrilled to combine Synaffix’s conjugation and linker-payload technologies with our custom-designed antibodies to create next-generation ADCs for patients with high unmet medical needs.”
Did you find this insightful? Subscribe for more.
APR Team
African Pharmaceutical Review team dedicated to providing the latest news, insights and developments from the pharma, biotech and medtech industries.